Concord Drugs (BOM:538965) Interest Expense: ₹-17.1 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:538965 Concord Drugs Ltd BOM:538965
70 GF Score
Price ₹72.89
GF Value ₹61.08
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Concord Drugs Interest Expense?

Concord Drugs BOM:538965 +3.32% 70 Interest Expense is ₹-17.1 Mil as of Mar. 2026. GuruFocus rates BOM:538965 with a GF Score™ of 70/100 and a GF Value™ of ₹61.08 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Concord Drugs's interest expense for the three months ended in Mar. 2026 was ₹ -4.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-17.1 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Concord Drugs's Operating Income for the three months ended in Mar. 2026 was ₹ 11.4 Mil. Concord Drugs's Interest Expense for the three months ended in Mar. 2026 was ₹ -4.0 Mil. Concord Drugs's Interest Coverage for the quarter that ended in Mar. 2026 was 2.89. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Concord Drugs  (BOM:538965) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Concord Drugs's Interest Expense for the three months ended in Mar. 2026 was ₹-4.0 Mil. Its Operating Income for the three months ended in Mar. 2026 was ₹11.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was ₹18.1 Mil.

Concord Drugs's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*11.433/-3.957
=2.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Concord Drugs Interest Expense Historical Data

* Premium members only.

The historical data trend for Concord Drugs's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Drugs Interest Expense Chart

Concord Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.77 -17.28 -18.68 -20.27 -17.14

Concord Drugs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.11 -4.90 -4.88 -3.40 -3.96
BOM:538965
70GF Score
Concord Drugs Ltd BOM:538965
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Concord Drugs Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-17.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of ₹-17.1 Mil mean?
Concord Drugs (BOM:538965) has a Interest Expense of ₹-17.1 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Concord Drugs and its competitors.
Is Concord Drugs' Interest Expense too high?
Concord Drugs' current Interest Expense is ₹-17.1 Mil. Overall, Concord Drugs has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Concord Drugs' Interest Expense compare to ZTS?
Concord Drugs' Interest Expense of ₹-17.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Concord Drugs and its competitors. Concord Drugs's current Interest Expense is ₹-17.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Drugs stock overvalued right now?
Based on GuruFocus' analysis, Concord Drugs (BOM:538965) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹61.08, compared to a current price of ₹72.89 — trading 19.3% above its estimated fair value. The current Interest Expense is ₹-17.1 Mil. Concord Drugs' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Concord Drugs (BOM:538965), the current Interest Expense is ₹-17.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Concord Drugs (BOM:538965) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued. The current stock price of ₹72.89 is trading 19.3% above its estimated GF Value™ of ₹61.08. GuruFocus considers Concord Drugs to be Modestly Overvalued.

Key valuation signals for BOM:538965:

  • Interest Expense: ₹-17.1 Mil
  • GF Value™: ₹61.08 vs. price of ₹72.89 (19.3% above fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Concord Drugs Business Description

Address Survey No. 249, Brahmanapally Village, Hayatnagar Mandal, Ranga Reddy, Hyderabad, TG, IND, 501511
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
70GF Score

Get the complete analysis for BOM:538965

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹72.89
Price
₹61.08
GF Value